MétaCan
Menu
Retour à la cohorte
Enregistrement W2074621677 · doi:10.1111/j.1365-2125.2008.03215.x

Internet pharmacy: a web of mistrust?

2008· article· en· W2074621677 sur OpenAlexaboutno aff
Simon Maxwell, David J. Webb

Notice bibliographique

RevueBritish Journal of Clinical Pharmacology · 2008
Typearticle
Langueen
DomaineMedicine
ThématiquePharmaceutical Quality and Counterfeiting
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésPharmacyThe InternetWorld Wide WebMedicineInternet privacyFamily medicineComputer science

Résumé

récupéré en direct d'OpenAlex

Traditional models of access to medicines are under threat. For decades, to obtain the newest and most powerful medicines patients have needed a prescription, usually written by a doctor after consideration of a differential diagnosis at a face-to-face consultation, which is subsequently dispensed after presentation at a pharmacy (Figure 1). Each ‘prescription-only medicine’ (POM) available in this way has been carefully considered by regulatory authorities prior to granting of marketing authorization for specified prescribing indications. The availability of POMs is now limited further in some health services by the emergence of government agencies, such as the National Institute of Clinical Excellence in the UK, that restrict prescribing of medicines that are considered less cost-effective. In an information-rich age when patients expect (and have been promised [1]) greater empowerment, this tightly regulated, professionally led environment leaves some frustrated and disenfranchized, particularly if gaining access to the doctor is difficult (or costly). This barrier may be addressed, in part, by the emergence of new prescribing groups such as pharmacists and nurses [2] but, for most, free choice to self-medicate is limited to a small number of safer ‘over-the-counter’ medicines. Access to prescription-only medicines However, this carefully regulated system is being progressively bypassed by the boom in internet drug sales. The number of on-line pharmacies offering to sell POMs directly to consumers is growing rapidly, with annual sales from Canada alone estimated to be worth $726 million in 2005[3]. Medicines commonly accessed in this way include analgesics (e.g. oxycodone), anxiolytics and sedatives (e.g. diazepam), antidepressants (e.g. fluoxetine), stimulants (e.g. methyphenidate), anorectics (e.g. phentermine) and others that are generally considered as ‘lifestyle drugs’ (e.g. sildenafil for impotence, finasteride for hair loss). Although some internet pharmacies may offer medical support (‘cyber doctors’) or apply a diagnostic questionnaire to gauge suitability, many will sell drugs, some of which are controlled or high risk, without a prescription and without requiring a visit to a doctor [4]. POMs available in this way are accessed by approximately 4% of US adults [5]. Various motivations may persuade members of the public to purchase POMs via the internet, in most instances discarding the involvement of skilled healthcare professionals. Convenience is a key factor, particularly for those who are disabled or housebound, who can order medicines from their own home in unlimited quantity 24 h a day. Another is cost. Internet pharmacies often make branded or generic POMs available more cheaply. This underlies the phenomenal growth of Canadian sites selling to consumers forced to pay higher prices through the US market [3]. The internet sales model reduces overheads and provides a level of competition that cannot be matched by ‘bricks and mortar’ pharmacies. On-line pharmacies can also provide immediate access to a plethora of additional product information via hyperlinks and search programs. Some patients may have found it impossible to find a doctor willing to prescribe or able to prescribe the medicines they wish to take. Desperation may be a factor for those with serious or debilitating conditions (e.g. cancer [6]), where the best available healthcare has failed to match expectations. A final benefit for some is privacy, particularly valued for some lifestyle conditions that are a source of embarrassment or shunned by the medical establishments [7]. Other important trends have supported the growth of internet sales. There may be an increasing perception that prescription drugs, which carry the stamp of regulatory approval, are safe and constitute little more than another consumer item. This notion could be reinforced by the growing acceptance and prescription of analgesics and mood-stabilizing drugs and, in some countries, by widespread exposure to direct-to-consumer advertising [8]. The progressive affirmation of patient autonomy and empowerment in modern healthcare may have encouraged self-diagnosis and a willingness to procure the treatments thought necessary. Although on-line sales by legitimate providers, run on a sound professional basis, may undoubtedly provide benefits, serious concerns have emerged about the overall impact of the internet pharmacy sector on public health. Many less reputable sites are openly engaged in illegal on-line trafficking of controlled drugs, which are now available unrestricted, even to the young. There is now a cybermarket for illegal distribution of drugs that are either unapproved by regulatory authorities, dispensed without a valid prescription, illegal versions of prescription drugs (some ineffective, out of date or contaminated), marketed with fraudulent health claims, or intended for recreational or criminal use [e.g. gamma hydroxybutyrate (GHB) used for body building and incapacitating victims of ‘date rape’]. Not surprisingly, misuse of POMs is accounting for an increasing proportion of US emergency room visits [9], and there have also been numerous reports of serious adverse events or interactions following internet purchases [10]. Many sites also lack the most basic e-commerce security features, thus putting personal information at risk. Internet sales of POMs should now be recognized as a serious and growing public health issue that may ultimately pose a much greater threat to health than rofecoxib (Vioxx®) or any of the other recent medicines ‘scandals’. We believe that urgent action is now required to tackle the worst excesses of this trade, but also to protect the benefits of legitimate on-line operations. This will require a combination of legislation review, law enforcement and public education, each of which poses considerable challenges. There is a need to redefine, in the internet age, what constitutes a doctor–patient consultation, in what circumstances this can occur on-line and whether this can lead to a valid prescription (without which the supply of popular narcotics, sedatives, stimulants and anabolic steroids is already illegal in the UK and USA). Law enforcement agencies should take steps to block websites that breach these agreed basic professional standards. The ubiquitous nature of the internet requires a multinational approach to thwart the activities of those operating from countries where no relevant legal provisions are in place. There have already been some successes in enforcing current legislation [11], but we should recognize that the anonymity, ease of changing websites, use of multiple portals of access to anchor sites, and the potentially enormous profits to be made will mean that such measures are going to be only partially successful. It will clearly be important to bring together major stakeholders, including internet service provides, search engines, banks and credit agencies, and postal services as well as regulatory authorities. As for so many public health issues, improved education and raised awareness of the hazards will be crucial. Such information is already provided by the regulatory authorities in the UK and USA [12, 13], but is likely to be ineffective unless supported by campaigns through the media, internet search engines and service providers. These should highlight factors that suggest a less reputable site (e.g. failure to provide a physical address, lack of links to the national healthcare system, no requirement for a valid prescription, failure to ask for details about the patient or their doctor). Official approval of reputable businesses will also afford some protection for the unwary. Registration schemes for reputable businesses are already run by the Royal Pharmaceutical Society of Great Britain and the National Association of Boards of Pharmacy in the US and provide a model for the future [14, 15]. None to declare.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,002
score de la tête « metaresearch » (Gemma)0,001
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesCharge utile insuffisante (le modèle a refusé de juger)
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: Sans objet
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,247
Score d'incertitude au seuil0,998

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0020,001
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0010,001
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,001
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0030,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,246
Tête enseignante GPT0,495
Écart entre enseignants0,248 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeSans objet
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations7
Publié2008
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBritish Journal of Clinical PharmacologyMême sujetPharmaceutical Quality and CounterfeitingTravaux en français237 207